Genor Biopharma Holdings Limited
HKEX:6998.HK
1.65 (HKD) • At close November 14, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Revenue
| 0 | 15.932 | 0 | 10.331 | 13.039 | 6.882 |
| Cost of Revenue
| 0 | 0.983 | 0 | 2.596 | 9.562 | 5.452 |
| Gross Profit
| 0 | 14.949 | 0 | 7.735 | 3.477 | 1.43 |
| Gross Profit Ratio
| 0 | 0.938 | 0 | 0.749 | 0.267 | 0.208 |
| Reseach & Development Expenses
| 564.278 | 583.881 | 612.718 | 696.574 | 438.817 | 271.498 |
| General & Administrative Expenses
| 125.237 | 134.13 | 207.35 | 241.44 | 14.048 | 7.342 |
| Selling & Marketing Expenses
| 0 | 83.143 | 98.603 | 0 | 0 | 0 |
| SG&A
| 125.237 | 217.273 | 305.953 | 241.44 | 14.048 | 7.342 |
| Other Expenses
| 21.681 | 3.486 | -19.159 | -5.858 | 65.582 | 2.778 |
| Operating Expenses
| 711.196 | 801.154 | 899.512 | 932.156 | 518.447 | 281.618 |
| Operating Income
| -711.196 | -786.205 | -859.107 | -924.421 | -514.97 | -280.188 |
| Operating Income Ratio
| 0 | -49.348 | 0 | -89.48 | -39.495 | -40.713 |
| Total Other Income Expenses Net
| 33.7 | 50.299 | -7.199 | -133.288 | -3.065 | -7.889 |
| Income Before Tax
| -677.496 | -732.42 | -866.306 | -3,036.31 | -523.637 | -288.077 |
| Income Before Tax Ratio
| 0 | -45.972 | 0 | -293.903 | -40.159 | -41.859 |
| Income Tax Expense
| 2.28 | -2.024 | -0.932 | -5.806 | -0.891 | 1.534 |
| Net Income
| -674.362 | -730.396 | -865.374 | -3,030.504 | -522.746 | -289.611 |
| Net Income Ratio
| 0 | -45.845 | 0 | -293.341 | -40.091 | -42.082 |
| EPS
| -1.33 | -1.45 | -1.75 | -12.37 | -1.09 | -0.6 |
| EPS Diluted
| -1.33 | -1.45 | -1.74 | -12.37 | -1.09 | -0.6 |
| EBITDA
| -551.007 | -675.887 | -819.501 | -2,980.286 | -480.91 | -243.854 |
| EBITDA Ratio
| 0 | -42.423 | 0 | -288.427 | -36.774 | -35.211 |